These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
223 related items for PubMed ID: 18778680
1. Construction and testing of a novel host-range defective myxoma virus vaccine with the M063 gene inactivated that is non-permissive for replication in rabbit cells. Adams MM, van Leeuwen BH, McFadden G, Kerr PJ. Vet Res; 2008; 39(6):60. PubMed ID: 18778680 [Abstract] [Full Text] [Related]
2. Construction and evaluation of live attenuated myxoma virus vaccines with targeted virulence gene deletions. Adams MM, van Leeuwen BH, Kerr PJ. Vaccine; 2008 Oct 29; 26(46):5843-54. PubMed ID: 18789367 [Abstract] [Full Text] [Related]
3. Limitations of plasmid vaccines to complex viruses: selected myxoma virus antigens as DNA vaccines were not protective. Adams MM, van Leeuwen BH, Kerr PJ. Vaccine; 2004 Nov 25; 23(2):198-204. PubMed ID: 15531037 [Abstract] [Full Text] [Related]
4. Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. Barrett JW, Shun Chang C, Wang G, Werden SJ, Shao Z, Barrett C, Gao X, Belsito TA, Villenevue D, McFadden G. Virology; 2007 Apr 25; 361(1):123-32. PubMed ID: 17184804 [Abstract] [Full Text] [Related]
5. Coevolution of host and virus: cellular localization of virus in myxoma virus infection of resistant and susceptible European rabbits. Best SM, Collins SV, Kerr PJ. Virology; 2000 Nov 10; 277(1):76-91. PubMed ID: 11062038 [Abstract] [Full Text] [Related]
6. Isolation of an attenuated myxoma virus field strain that can confer protection against myxomatosis on contacts of vaccinates. Bárcena J, Pagès-Manté A, March R, Morales M, Ramírez MA, Sánchez-Vizcaíno JM, Torres JM. Arch Virol; 2000 Nov 10; 145(4):759-71. PubMed ID: 10893154 [Abstract] [Full Text] [Related]
7. Virulence and pathogenesis of the MSW and MSD strains of Californian myxoma virus in European rabbits with genetic resistance to myxomatosis compared to rabbits with no genetic resistance. Silvers L, Inglis B, Labudovic A, Janssens PA, van Leeuwen BH, Kerr PJ. Virology; 2006 Apr 25; 348(1):72-83. PubMed ID: 16442580 [Abstract] [Full Text] [Related]
8. A pathogenic myxoma virus in vaccinated and non-vaccinated commercial rabbits. Kritas SK, Dovas C, Fortomaris P, Petridou E, Farsang A, Koptopoulos G. Res Vet Sci; 2008 Dec 25; 85(3):622-4. PubMed ID: 18455207 [Abstract] [Full Text] [Related]
9. Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits. Opgenorth A, Nation N, Graham K, McFadden G. Virology; 1993 Feb 25; 192(2):701-9. PubMed ID: 8380671 [Abstract] [Full Text] [Related]
10. Myxoma virus M130R is a novel virulence factor required for lethal myxomatosis in rabbits. Barrett JW, Werden SJ, Wang F, McKillop WM, Jimenez J, Villeneuve D, McFadden G, Dekaban GA. Virus Res; 2009 Sep 25; 144(1-2):258-65. PubMed ID: 19477207 [Abstract] [Full Text] [Related]
11. A Vero cell-attenuated Goatpox virus provides protection against virulent virus challenge. Hosamani M, Nandi S, Mondal B, Singh RK, Rasool TJ, Bandyopadhyay SK. Acta Virol; 2004 Sep 25; 48(1):15-21. PubMed ID: 15230470 [Abstract] [Full Text] [Related]
12. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Carroll MW, Moss B. Virology; 1997 Nov 24; 238(2):198-211. PubMed ID: 9400593 [Abstract] [Full Text] [Related]
13. Genetic Variability of Myxoma Virus Genomes. Braun C, Thürmer A, Daniel R, Schultz AK, Bulla I, Schirrmeier H, Mayer D, Neubert A, Czerny CP. J Virol; 2017 Feb 15; 91(4):. PubMed ID: 27903800 [Abstract] [Full Text] [Related]
14. Molecular characterization of SG33 and Borghi vaccines used against myxomatosis. Cavadini P, Botti G, Barbieri I, Lavazza A, Capucci L. Vaccine; 2010 Jul 26; 28(33):5414-20. PubMed ID: 20598407 [Abstract] [Full Text] [Related]
15. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G. J Infect Dis; 2009 Jan 01; 199(1):39-48. PubMed ID: 19012492 [Abstract] [Full Text] [Related]
16. [Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA]. Mahnel H, Mayr A. Berl Munch Tierarztl Wochenschr; 1994 Aug 01; 107(8):253-6. PubMed ID: 7945180 [Abstract] [Full Text] [Related]
17. Leporine acquired immune deficiency disease. Sell S, Strayer D, Skaletsky E, Corbeil L, Cabirac G, Leibowitz J. Symp Fundam Cancer Res; 1986 Aug 01; 38():97-111. PubMed ID: 3018882 [Abstract] [Full Text] [Related]
18. Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis. Lalani AS, Masters J, Graham K, Liu L, Lucas A, McFadden G. Virology; 1999 Apr 10; 256(2):233-45. PubMed ID: 10191189 [Abstract] [Full Text] [Related]
19. Coevolution of host and virus: the pathogenesis of virulent and attenuated strains of myxoma virus in resistant and susceptible European rabbits. Best SM, Kerr PJ. Virology; 2000 Feb 01; 267(1):36-48. PubMed ID: 10648181 [Abstract] [Full Text] [Related]
20. A vero cell derived combined vaccine against sheep pox and Peste des Petits ruminants for sheep. Chaudhary SS, Pandey KD, Singh RP, Verma PC, Gupta PK. Vaccine; 2009 Apr 28; 27(19):2548-53. PubMed ID: 19428860 [Abstract] [Full Text] [Related] Page: [Next] [New Search]